Estrella Immunopharma, Inc. financial data

Symbol
ESLA, ESLAW on Nasdaq
Location
Emeryville, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 20.5 % -96.9%
Debt-to-equity -169 % -1126%
Return On Equity -156 % -191%
Return On Assets -134 % -125%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.8M shares +4.35%
Common Stock, Shares, Outstanding 37.8M shares
Entity Public Float 40M USD
Common Stock, Value, Issued 3.83K USD +4.56%
Weighted Average Number of Shares Outstanding, Basic 37.1M shares +2.45%
Weighted Average Number of Shares Outstanding, Diluted 37.1M shares +2.45%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.15M USD +46.9%
General and Administrative Expense 649K USD +17.8%
Operating Income (Loss) -4.8M USD -42.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -4.8M USD -42.2%
Income Tax Expense (Benefit) 850 USD -47.7%
Net Income (Loss) Attributable to Parent -4.8M USD -42.2%
Earnings Per Share, Basic -0.13 USD/shares -44.4%
Earnings Per Share, Diluted -0.13 USD/shares -44.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.63M USD -9.51%
Accounts Receivable, after Allowance for Credit Loss, Current 273K USD
Assets, Current 2.02M USD -9.47%
Operating Lease, Right-of-Use Asset 0 USD
Assets 3.52M USD -5.67%
Accrued Liabilities, Current 167K USD
Liabilities, Current 13.4M USD +347%
Deferred Income Tax Liabilities, Net 8.37K USD
Other Liabilities, Noncurrent 12.7K USD
Liabilities 13.4M USD +347%
Retained Earnings (Accumulated Deficit) -36.4M USD -59%
Stockholders' Equity Attributable to Parent -9.84M USD -1418%
Liabilities and Equity 3.52M USD -5.67%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -466K USD +89%
Net Cash Provided by (Used in) Financing Activities -29.5K USD +65%
Net Cash Provided by (Used in) Investing Activities -112K USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 38.3M shares +4.56%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.4K USD +92.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.63M USD -9.51%
Deferred Tax Assets, Valuation Allowance 5.4M USD
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 5.4M USD
Deferred Income Tax Expense (Benefit) -21.7K USD
Deferred Tax Assets, Operating Loss Carryforwards 2.43M USD
Preferred Stock, Shares Authorized 1M shares 0%
Additional Paid in Capital 27.1M USD +12.5%
Current State and Local Tax Expense (Benefit) 0 USD
Current Federal Tax Expense (Benefit) 113K USD
Share-based Payment Arrangement, Expense 152K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%